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Introduction: Although the pathogenesis of systemic sclerosis (SSc) still remains unknown, recent studies have
demonstrated that endothelins are deeply involved in the developmental process of fibrosis and vasculopathy
associated with SSc, and a dual endothelin receptor antagonist, bosentan, has a potential to serve as a disease
modifying drug for this disorder. Importantly, endothelin-1 (ET-1) exerts a pro-fibrotic effect on normal dermal
fibroblasts and bosentan reverses the pro-fibrotic phenotype of SSc dermal fibroblasts. The purpose of this study
was to clarify the details of molecular mechanisms underlying the effects of ET-1 and bosentan on dermal
fibroblasts, which have not been well studied.
Methods: The mRNA levels of target genes and the expression and phosphorylation levels of target proteins were
determined by reverse transcription real-time PCR and immunoblotting, respectively. Promoter assays were
performed using a sequential deletion of human α2 (I) collagen (COL1A2) promoter. DNA affinity precipitation and
chromatin immunoprecipitation were employed to evaluate the DNA binding ability of Fli1. Fli1 protein levels in
murine skin were evaluated by immunostaining.
Results: In normal fibroblasts, ET-1 activated c-Abl and protein kinase C (PKC)-δ and induced Fli1 phosphorylation
at threonine 312, leading to the decreased DNA binding of Fli1, a potent repressor of the COL1A2 gene, and the
increase in type I collagen expression. On the other hand, bosentan reduced the expression of c-Abl and PKC-δ,
the nuclear localization of PKC-δ, and Fli1 phosphorylation, resulting in the increased DNA binding of Fli1 and the
suppression of type I collagen expression in SSc fibroblasts. In bleomycin-treated mice, bosentan prevented dermal
fibrosis and increased Fli1 expression in lesional dermal fibroblasts.
Conclusions: ET-1 exerts a potent pro-fibrotic effect on normal fibroblasts by activating “c-Abl - PKC-δ - Fli1”
pathway. Bosentan reverses the pro-fibrotic phenotype of SSc fibroblasts and prevents the development of dermal
fibrosis in bleomycin-treated mice by blocking this signaling pathway. Although the efficacy of bosentan for dermal
and pulmonary fibrosis is limited in SSc, the present observation definitely provides us with a useful clue to further
explore the potential of the upcoming new dual endothelin receptor antagonists as disease modifying drugs for SSc.* Correspondence: yasano-tky@umin.ac.jp
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Systemic sclerosis (SSc) is a multisystem connective tissue
disease characterized by immune abnormalities, vascular
injuries, and fibrosis of skin and certain internal organs
[1]. Although the pathogenesis of SSc still remains unclear,
it has been believed that fibroblast activation is a final con-
sequence following inflammation, autoimmune attacks,
and vascular damage. A wealth of evidence suggests that,
once activated, SSc dermal fibroblasts establish a self-
activation system by autocrine transforming growth factor
(TGF)-β stimulation at least partially via upregulating cell
surface receptors for latent-form TGF-β, such as integrin
αVβ3, integrin αVβ5, and thrombospondin-1 [2-6]. A
plausible strategy to treat fibrosis in SSc is to block the
autocrine TGF-β signaling in SSc fibroblasts and better
understanding of its molecular mechanism is necessary to
develop the treatment for this complicated disorder [1,7].
The endothelins are a family of 21-amino-acid peptides
mainly produced by endothelial cells, which consist of three
isoforms, including endothelin-1 (ET-1) and the related
peptides endothelin-2 and -3. In addition to a potent vaso-
constrictive effect, ET-1 possesses a wide range of biological
effects on different cell types. Several lines of evidence have
demonstrated that ET-1 plays a pivotal role in the process
of fibroblast activation as a downstream target of TGF-β
[8-11]. TGF-β1 induces the expression of ET-1 through
Smad- and activator protein-1/c-Jun N-terminal kinase-
dependent signaling in human dermal fibroblasts, while
through a Smad-independent ALK5/activator protein-1/c-
Jun N-terminal kinase-dependent signaling in human lung
fibroblasts, and the ability of TGF-β1 to trigger the pro-
fibrotic gene program is dependent on ET-1 in both of
these cells [9,12]. In animal models, forced expression of
ET-1 accelerates dermal wound healing as well as TGF-β1,
while blockade of endothelin signaling with bosentan, a
dual endothelin receptor antagonist, significantly in-
hibits the effect of TGF-β1 on dermal wound healing
[12]. Importantly, bosentan also attenuates bleomycin
(BLM)-induced skin fibrosis in animal models [12].
Thus, endothelins are potentially implicated in the
pathogenesis of fibrotic disorders.
The role of ET-1 has also been well-studied in SSc. Cir-
culating ET-1 levels are elevated in diffuse cutaneous SSc
and limited cutaneous SSc patients compared with healthy
controls, and in limited cutaneous SSc patients with pul-
monary arterial hypertension as compared to those without
[13,14], suggesting the involvement of ET-1 in the develop-
ment of fibrotic and vascular involvement associated with
SSc. Clinically, bosentan has been shown to prevent the de-
velopment of new digital ulcers in SSc patients by two
high-quality randomized clinical trials [15,16]. As for pul-
monary arterial hypertension associated with SSc, bosentan
mostly prevents the exacerbation of hemodynamic pa-
rameters and improves exercise tolerance evaluated by6-minute walk distance [17-19]. These clinical data suggest
that bosentan is useful for the treatment of vascular in-
volvement in SSc. In contrast, the clinical efficacy of
bosentan for interstitial lung disease (ILD) is relatively
limited [20,21], though bosentan reverses the pro-fibrotic
phenotype of cultured SSc lung fibroblasts [8-11]. Since
this discrepancy between experimental data and clinical
observation may be partly due to the relatively lower tissue
distribution of bosentan (approximately 1%) [22], endothe-
lin receptor antagonists with better tissue distribution have
a potential to improve the pathological fibrosis in SSc.
As described above, although ET-1 is a potent pro-
fibrotic peptide and bosentan exerts a novel anti-fibrotic
effect, the detailed molecular mechanism explaining
these observations has still remained unknown. There-
fore, we herein investigated the mechanisms by which
ET-1 drives a pro-fibrotic gene program in normal der-
mal fibroblasts and bosentan reverses the pro-fibrotic
phenotype of SSc dermal fibroblasts and the experimen-
tal dermal fibrosis in animal models.
Methods
Reagents
Anti-Fli1 antibody for immunoblotting and immunofluores-
cence and anti-protein kinase C (PKC)-δ antibody were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-Fli1 antibody for immunohistochemistry was
obtained from BD Biosciences (San Diego, CA, USA). Anti-
bodies against c-Abl and phospho-c-Abl (Tyr245) were
bought from Cell Signaling (Danvers, MA, USA). Antibodies
for β-actin and α-smooth muscle actin (α-SMA) and anti-
body for type I collagen were products from Sigma-Aldrich
(St. Louis, MO) and Southern Biotech (Birmingham, AL,
USA), respectively. The polyclonal rabbit anti-phospho-
Fli1 (Thr312)-specific antibody was generated as described
previously [23]. Bosentan was a gift from Actelion Phar-
maceuticals (Allschwil, Switzerland). Smad3 inhibitor SIS3
was purchased from Calbiochem (San Diego, CA, USA).
Cell cultures
Human dermal fibroblasts were obtained by skin biopsy
from the affected areas (dorsal forearm) of eight patients
with diffuse cutaneous SSc with less than 2 years of skin
thickening and from the corresponding area of eight closely
matched healthy donors. Fibroblasts were cultured in
Dulbecco’s modified eagle medium with 10% fetal calf
serum, 2 mM L-glutamine, and the antibiotic antimycotic
solution. These cells were individually maintained as mono-
layers at 37°C in 95% air, 5% CO2. All studies used cells
from passage number three to six. The study was per-
formed according to the Declaration of Helsinki and ap-
proved by the ethical committee of the University of Tokyo
Graduate School of Medicine. Written informed consent
was obtained from all of the patients and healthy controls.
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Cell viability was evaluated by the trypan blue exclusion
test. Cells were treated with the indicated concentration of
bosentan. Cell viability was examined at 24 and 48 hours.
Stained (dead) and unstained (viable) cells were counted
with a hematocytometer.
Immunoblotting
Confluent quiescent fibroblasts were serum-starved for
48 hours and harvested. In some experiments, cells were
stimulated with ET-1 or bosentan for the indicated
period of time before being harvested. Whole cell lysates
and nuclear extracts were prepared as described previ-
ously [2,24]. Samples were subjected to sodium dodecyl
sulfate-polyacrylamide gels electrophoresis and immuno-
blotting with the indicated primary antibodies. Bands
were detected using enhanced chemiluminescent tech-
niques (Thermo Scientific, Rockford, IL, USA). Accord-
ing to a series of pilot experiments, anti-Fli1 antibody
and anti-phospho-Fli1 (Thr312)-specific antibody work
much better in immunoblotting using nuclear extracts
and whole cell lysates, respectively.
RNA isolation and reverse transcription (RT) real-time PCR
Total RNA was isolated from normal and SSc fibroblasts
with RNeasy spin columns (Qiagen, Crawley, UK). One μg
of total RNA from each sample was reverse-transcribed
into cDNA using the iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA, USA). Real-time quantitative PCR was
performed using Fast SYBR Green PCR Master Mix
(Applied Biosystems, Carlsbad, CA, USA) on ABI prism
7000 (Applied Biosystems) in triplicates. Human α2 (I)
collagen (COL1A2) and Fli1 mRNA levels were normal-
ized to human 18S rRNA mRNA levels. The sequences of
primers for COL1A2, Fli1, and 18S rRNA were obtained
from previous publications [25,26]. The ΔΔCt method was
used to compare target gene and housekeeping gene (18S
rRNA) mRNA expression.
Plasmid construction
Generation of a series of 5′-deletions of COL1A2/
chloramphenicol acetyltransferase (CAT) construct con-
sisting of the COL1A2 gene fragments (+58 to −353, −264,
−186, or −108 bp relative to the transcription start site)
linked to the CAT reporter gene was done as previously
described [27,28].
The evaluation of COL1A2 promoter activity by RT
real-time PCR
Normal or SSc fibroblasts were grown to 50% conflu-
ence in 100-mm dishes, transfected with the indicated
constructs along with pSV-β-galactosidase (β-GAL) using
FuGENE6 (Roche Diagnostics, Indianapolis, IN, USA).
After overnight incubation at 37°C, some cells werefurther stimulated with ET-1 or bosentan for 24 hours.
The cells were harvested and CAT and β-GAL mRNA
levels were determined using RT real-time PCR. Transfec-
tion efficiency was normalized by β-GAL mRNA levels.
In some samples, it was confirmed that this method re-
produces the results of relative promoter activity evalu-
ated by the canonical method of CAT reporter assay
using [14C]-chloramphenicol. The sequences of primers
were as follows: CAT forward 5′-TTCGTCTCAGCCA
ATCCCTGGGTGA-3′ and reverse 5′-CCCATCGTGA
AAACGGGGGCGAA-3′; β-GAL forward 5′-TCCACC
TTCCCTGCGTTA-3′ and reverse 5′-AGAAGTCGGG
AGGTTGCTG-3′.
DNA affinity precipitation assay
DNA affinity precipitation assay was performed as de-
scribed previously [29]. Briefly, nuclear extracts prepared
from dermal fibroblasts were incubated for 10 minutes at
4°C with gel shift binding buffer, and 20 μg of poly (dI-dC)
in a final volume of 1 ml. Pre-clearing was performed by
adding streptavidin-coupled agarose beads and incubating
the mixture for 30 minutes at 4°C. After centrifugation,
the supernatant was incubated with 500 pM of COL1A2-
EBS oligonucleotide, which corresponds to bp −307
to −269 of COL1A2 promoter, or COL1A2-EBS-M oligo-
nucleotide, which has a mutated Ets binding site (EBS) of
COL1A2-EBS oligonucleotide, overnight at 4°C. Then,
streptavidin-coated agarose beads were added, followed by
a further 2-hour incubation at 4°C. The protein-DNA-
streptavidin-agarose complex was washed twice with Tris-
ethylenediaminetetraacetic acid (EDTA) including 100
mM NaCl, twice with gel shift binding buffer, and once
with PBS. Precipitates were subjected to immunoblotting
with anti-Fli1 antibody.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was carried out using EpiQuik ChIP kit
(Epigentek, Farmingdale, NY, USA). Briefly, cells were
treated with 1% formaldehyde for 10 minutes. The
cross-linked chromatin was then prepared and soni-
cated to an average size of 300 to 500 bp. The DNA
fragments were immunoprecipitated with anti-Fli1 anti-
body at 4°C. As a negative control, normal rabbit IgG
was used. After reversal of crosslinking, the immuno-
precipitated chromatin was quantified by RT real-time
PCR. The primers were as follows: COL1A2/F-404, 5′-
CTGGACAGCTCCTGCTTTGAT-3′; COL1A2/R-233,
5′-CTTTCAAGGGGAAACTCTGACTC-3′.
BLM-induced murine model of SSc
BLM (Nippon Kayaku, Tokyo, Japan) or PBS was
injected subcutaneously into the back of C57BL/6 mice
daily for 3 weeks, as described previously [30].
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Immunohistochemistry with Vectastain ABC kit (Vector
Laboratories, Burlingame, CA, USA) was performed on
formalin-fixed, paraffin-embedded tissue sections using
anti-Fli1 antibody according to the manufacturer’s
instruction.
Immunofluorescence
Rabbit anti-Fli1 antibody and mouse anti-α-SMA antibody
were used as primary antibodies and Alexa Fluor 546 goat
anti-rabbit IgG antibody (Invitrogen, Carlsbad, CA, USA)
and fluorescein isothiocyanate (FITC)-conjugated rat anti-
mouse IgG antibody (Roche) were used as secondary anti-
bodies. Coverslips were mounted by using Vectashield
with DAPI (Vector Laboratories), and staining was exam-
ined by using Bio Zero BZ-8000 (Keyence, Osaka, Japan)
at 495 nm (green), 565 nm (red), and 400 nm (blue).
Statistical analysis
Statistical analysis was carried out with the Mann-
Whitney U-test to compare the distributions of two
unmatched groups. The paired t-test was used for the
comparison of paired data after confirming the normal
distribution. Statistical significance was defined as a
P-value of <0.05.
Results
ET-1 rapidly induced the expression of type I collagen via
the non-Smad signaling pathway
As an initial experiment, to determine the optimal dose
of ET-1 to induce the expression of type I collagen in
normal dermal fibroblasts, cells were treated with ET-1
at the concentration of 0, 50, 100, 200, or 400 nM for
24 hours and mRNA levels of the COL1A2 gene were
determined by RT real-time PCR. As shown in Figure 1A,
ET-1 significantly increased the mRNA levels of the
COL1A2 gene at the concentration of 200 nM. To fur-
ther confirm this finding at protein levels, the levels of
type I collagen protein were determined by immunoblot-
ting under the same conditions. As shown in Figure 1B,
ET-1 induced the expression of type I collagen protein
in a dose-dependent manner, reaching a peak at the
concentration of 200 nM. Therefore, in the following
studies, we stimulated cells with ET-1 at the concentration
of 200 nM.
We next investigated the time course of ET-1-
dependent induction of type I collagen in normal dermal
fibroblasts. As shown in Figure 1C, the increase in the
mRNA levels of the COL1A2 gene was observed mod-
estly but significantly as early as 15 minutes and reached
a maximum around 30 to 60 minutes after the ET-1
stimulation. This observation was also reproduced at
protein levels by immunoblotting (Figure 1D). As Smad3
has a big impact on the TGF-β-dependent regulation oftype I collagen expression, we also investigated the effect
of Smad3 inhibitor SIS3 on the ET-1-induced mRNA ex-
pression of the COL1A2 gene. As shown in Figure 1E,
SIS3 did not affect the mRNA levels of the COL1A2
gene induced by ET-1 stimulation. Collectively, these re-
sults indicate that ET-1 rapidly increases the expression
of type I collagen via the non-Smad signaling pathway.
The responsive element of COL1A2 promoter to ET-1 was
located between −353 and −264 bp, which includes the
Fli1 binding site
To identify potential regulatory elements of the COL1A2
gene by ET-1, we performed a reporter analysis using a
series of 5′-deletions of the COL1A2/CAT construct. As
basal promoter activities of these constructs have been
well-studied in our previous reports [31], we focused on
the difference in the fold increase of each promoter ac-
tivity induced by ET-1 stimulation. As shown in Figure 2,
ET-1 significantly increased the promoter activity of
the −353 COL1A2/CAT construct, whereas ET-1 totally
lost its stimulatory effect on the promoter activity of
the −264, −186, and −108 COL1A2/CAT constructs. These
results indicate that the responsive element of COL1A2
promoter to ET-1 is located between −353 and −264 bp.
Given that ET-1 increases the mRNA expression of the
COL1A2 gene independently of Smad3, ET-1 potentially
exerts its stimulatory effect on the COL1A2 gene by inacti-
vating transcriptional repressor(s). As the binding site of
Fli1, a potent repressor of the COL1A2 gene, is located at
−285 to −282 bp [32], we speculated that Fli1 may play a
central role in the ET-1-dependent regulation of the
COL1A2 gene expression.
ET-1 induced the phosphorylation of Fli1 at threonine
312 and decreased its binding to the COL1A2 promoter
To confirm the hypothesis described above, we asked if
ET-1 regulates the transcriptional activity of Fli1 in normal
dermal fibroblasts. Our previous studies reported that
transcriptional activity of Fli1 is tightly regulated by the
phosphorylation-acetylation cascade triggered by PKC-δ-
dependent phosphorylation of Fli1 at threonine 312 [23].
Phosphorylated Fli1 is subsequently acetylated by p300/
CBP-associated factor at lysine 380, resulting in the loss of
DNA binding ability [29] and degradation through the
proteasomal pathway (unpublished data). As the phos-
phorylation of Fli1 at threonine 312 is a critical step regu-
lating Fli1 transcriptional activity, we initially looked at the
effect of ET-1 on the phosphorylation levels of Fli1 at
threonine 312. As shown in Figure 3A, consistent with
our hypothesis, Fli1 was phosphorylated at threonine 312
by ET-1 as early as 15 minutes after the stimulation. To
further confirm if ET-1 decreases the binding ability of
Fli1 to COL1A2 promoter, we employed the DNA affin-
ity precipitation assay. As shown in Figure 3B, ET-1
Figure 1 Endothelin-1 (ET-1) induced the expression of type I collage through the non-Smad pathway in normal dermal fibroblasts.
A, B. Quiescent normal dermal fibroblasts were treated with the indicated concentration of ET-1 for 24 hours. mRNA levels of the human α2
(I) collagen (COL1A2) gene were determined by reverse transcription (RT) real-time PCR (A). Under the same condition, whole cell lysates were
subjected to immunoblotting with anti-type I collagen antibody (B). (C, D) Quiescent normal dermal fibroblasts were treated with 200 nM of ET-1
for the indicated period of time. mRNA levels of the COL1A2 gene (C) and the protein levels of type I collagen in whole cell lysates (D) were
evaluated by RT real-time PCR and immunoblotting, respectively. (E) Quiescent normal dermal fibroblasts were treated with SIS3 (3 μM) or
methanol. One hour later, some of the cells were treated with 200 nM of ET-1 for 3 or 24 hours. mRNA levels of the COL1A2 gene were assessed
by RT real-time PCR. The graph represents fold change in mRNA levels of the COL1A2 gene and protein levels of type I collagen, which were
quantified by densitometry, in response to ET-1 in comparison to unstimulated controls, which were arbitrarily set at 1. *P <0.05 versus control
cells untreated with ET-1. α1(I), α1(I) procollagen; α2(I), α2(I) procollagen; AU, arbitrary unit.
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early as 15 minutes, consistent with the results of im-
munoblotting. This observation was also confirmed
in vivo by ChIP analysis showing that ET-1 decreased the
association of Fli1 with the COL1A2 promoter at 3 hours
after stimulation (Figure 3C). Taken together, these results
indicate that ET-1 increases the promoter activity of theCOL1A2 gene by attenuating the DNA binding of Fli1
through its phosphorylation at threonine 312.
ET-1 promoted the nuclear localization of PKC-δ by
activating c-Abl
We previously disclosed that sequential activation of c-
Abl and PKC-δ is necessary for Fli1 phosphorylation at
Figure 2 Identification of the responsive element to endothelin-1 (ET-1) stimulation in the human α2 (I) collagen (COL1A2) promoter.
Normal dermal fibroblasts were transfected with 2 μg of the indicated 5′-deletion of the COL1A2/CAT construct and incubated for 48 hours. In
some experiments, cells were treated with ET-1 (200 nM) for the last 24 hours. Values represent CAT mRNA levels relative to those of untreated
cells transfected with the same COL1A2/CAT construct (100). The mean and SD from five separate experiments are shown. *P <0.05 versus control
cells untreated with ET-1.
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Therefore, we next examined if ET-1 stimulation se-
quentially activates c-Abl and PKC-δ in normal dermal
fibroblasts. As TGF-β1 increases the expression levels of
c-Abl and PKC-δ in normal dermal fibroblasts [34,35],
we looked at the effect of ET-1 on the expression levels
of c-Abl and PKC-δ by immunoblotting. As shown in
Figure 4A, the expression levels of c-Abl and PKC-δ
were markedly increased as early as 15 minutes after the
ET-1 stimulation in normal dermal fibroblasts. Given
that the phosphorylation levels of c-Abl reflect its activa-
tion status and nuclear localization is required for PKC-
δ to directly phosphorylate Fli1, we also evaluated the
phosphorylation levels of c-Abl and nuclear localization
of PKC-δ under the same condition. Consistently, ET-1
increased the phosphorylation levels of c-Abl (Figure 4A)
and promoted the nuclear translocation of PKC-δ
(Figure 4B) in normal dermal fibroblasts. Collectively,
these results indicate that ET-1 stimulation activates the
c-Abl/PKC-δ/Fli1 pathway and induces the expression of
the COL1A2 gene.
Bosentan, a dual endothelin receptor antagonist,
decreased the expression of the COL1A2 gene by
reversing the transcriptional activity of Fli1 in SSc dermal
fibroblasts
Previous reports demonstrated that bosentan, a dual ET
receptor antagonist, reverses a pro-fibrotic phenotype of
SSc fibroblasts [8]. However, the detailed mechanism by
which bosentan exerts its prominent anti-fibrotic effect onSSc fibroblasts has still remained unknown. We previously
demonstrated that Fli1 deficiency contributes to the estab-
lishment of the pro-fibrotic phenotype in SSc fibroblasts
and imatinib mesylate, which targets the c-Abl/PKC-δ/
Fli1 pathway, reverses the pro-fibrotic phenotype of these
cells [33,36]. Given that SSc fibroblasts are constitutively
activated by autocrine stimulation of transforming growth
factor- β (TGF-β), a potent inducer of ET-1, and produces
an excessive amount of ET-1 [4,9,31,37,38], autocrine ET-
1 appears to be involved in the self-activation system in
SSc fibroblasts. The present observation that ET-1 inacti-
vates the transcriptional activity of Fli1 suggests that the
blockade of autocrine ET-1 by bosentan reverses the pro-
fibrotic phenotype of SSc fibroblasts by reactivating the
transcriptional repressor activity of Fli1. To address this
issue, we performed a series of experiments using cultured
SSc dermal fibroblasts.
Supporting the contribution of autocrine ET-1 to the ac-
tivation of SSc dermal fibroblasts, exogenous ET-1 did not
affect type I collagen expression (Figure 5A), whereas
bosentan suppressed the expression of type I collagen in a
dose-dependent manner without any effect on cell viability
in SSc dermal fibroblasts (Figure 5B and Table 1). Further-
more, the total levels and the phosphorylation levels of c-
Abl and the total levels and nuclear localization of PKC-δ
were decreased in SSc dermal fibroblasts treated with
bosentan (Figure 5C and 5D). Consistently, Fli1 phosphor-
ylation at threonine 312 was reduced (Figure 5E) and the
occupancy of Fli1 on COL1A2 promoter was increased in
SSc dermal fibroblasts treated with bosentan (Figure 5F).
Figure 3 Endothelin-1 (ET-1) decreased the binding of Fli1 to the human α2 (I) collagen (COL1A2) promoter via increasing its
phosphorylation at threonine 312. (A) Normal dermal fibroblasts were treated with ET-1 for the indicated period of time. Whole cell lysates
were subjected to immunoblotting with anti-p-Fli1 antibody. To determine the total Fli1 levels, nuclear extracts were used for immunoblotting
with anti-Fli1 antibody. (B) Nuclear extracts were incubated with biotin-labeled oligonucleotides. Proteins bound to these nucleotides were
isolated with streptavidin-agarose beads, and Fli1 was detected by immunoblotting. Total Fli1 protein levels were determined by immunoblotting
using the same nuclear extracts. (C) Chromatin was isolated from normal dermal fibroblasts and immunoprecipitated using rabbit anti-Fli1
antibody or rabbit IgG. After isolation of bound DNA, PCR amplification was carried out using COL1A2 promoter-specific primers. Input DNA was
taken from each sample before addition of an antibody. The cycle threshold (Ct) values from IgG and Fli1 pull-down were subtracted by the
number obtained from 10 × diluted input DNA. The relative pull-down of Fli1 was then normalized by the subtracted Ct value of IgG. The mean
value of normal dermal fibroblasts without ET-1 stimulation was arbitrarily set at 1. All bands show one representative of three independent
experiments. DNAP, DNA affinity precipitation; AU, arbitrary unit.
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the FLI1 gene in SSc dermal fibroblasts (Figure 5G). Col-
lectively, these results indicate that autocrine ET-1 con-
tributes to the activation of SSc dermal fibroblasts and
bosentan reverses a pro-fibrotic phenotype of SSc dermal
fibroblasts by increasing the DNA binding ability of Fli1.Bosentan increased the expression of Fli1 protein in
lesional dermal fibroblasts of the BLM-induced murine
model of SSc
Finally, we investigated if bosentan increases the expres-
sion of Fli1 protein in lesional dermal fibroblasts of the
BLM-induced SSc murine model because previous reports
Figure 4 Endothelin-1 (ET-1) promoted the nuclear localization of protein kinase C (PKC)-δ by activating c-Abl. (A) Normal dermal
fibroblasts were treated with 200 nM of ET-1 for the indicated period of time. The protein levels of c-Abl, PKC-δ, and β-actin and the phosphorylation
levels of c-Abl were determined by immunoblotting using whole cell lysates (WCL). (B) Normal dermal fibroblasts were treated with ET-1 for 30 minutes
and cytoplasmic and nuclear extracts were prepared. The protein levels of PKC-δ in the cytoplasm and nucleus were determined by immunoblotting.
Equal amounts of loading were confirmed by immunoblotting for β-actin in cytoplasmic extracts and for TATA binding protein (TBP) in nuclear extracts.
The values below each blot represent the relative levels of target molecules normalized by loading controls with densitometry.
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dermal fibrosis in this model [12]. As we could reproduce
the preventive effect of bosentan on dermal fibrosis in
BLM-treated mice (Figure 6A), we carried out immuno-
staining for Fli1 in the skin samples taken from these
mice. As shown in Figure 6B, in the absence of bosentan,
the number of Fli1-positive dermal fibroblasts was much
more decreased in dermal fibroblasts of BLM-treated mice
than in those of PBS-treated mice. In contrast, when ad-
ministered bosentan, the number of Fli1-positive dermal
fibroblasts was comparable between BLM-treated mice
and PBS-treated mice. Importantly, the signals of Fli1 and
α-SMA, a marker of myofibroblasts, in double immuno-
fluorescence were mutually exclusive in most of dermal fi-
broblasts (Figure 6C), indicating that Fli1 expression is
closely related to the inactivation of dermal fibroblasts
in vivo. Collectively, these results suggest that bosentanprevents the development of dermal fibrosis in the BLM-
induced SSc murine model, at least partially, by increasing
the expression of Fli1 protein in lesional dermal fibroblasts.
Discussion
This study was undertaken to clarify the molecular mech-
anism underlying the pro-fibrotic effect of ET-1 on normal
dermal fibroblasts and anti-fibrotic effect of bosentan on
SSc dermal fibroblasts. A series of experiments demon-
strated that ET-1 activates the c-Abl/PKC-δ/Fli1 pathway
and reduces the DNA binding ability of Fli1, resulting in
the induction of type I collagen expression. Given that a
pro-fibrotic phenotype of SSc fibroblasts is largely due to
stimulation by autocrine TGF-β, a potent inducer of ET-1,
and those cells produce a much larger amount of ET-1
than normal dermal fibroblasts [1,7,38], it was speculated
that the blockade of ET-1-dependent signaling by bosentan
Figure 5 Bosentan reversed the pro-fibrotic phenotype of systemic sclerosis (SSc) dermal fibroblasts via increasing the DNA binding of
Fli1. (A-C) Whole cell lysates (WCL) prepared from SSc fibroblasts treated with endothelin-1 (ET-1) for 24 hours (A) or bosentan (BOS) for 48
hours (B, C) were subjected to immunoblotting (D) Protein kinase C (PKC)-δ levels were examined by immunoblotting in cytoplasmic
extracts (CE) and nuclear extracts (NE) prepared from SSc fibroblasts treated or untreated with bosentan for 48 hours. (E-G) SSc fibroblasts
were treated or untreated with bosentan for 48 hours. Fli1 phosphorylation levels and total Fli1 levels were determined by immunoblotting
(E). Fli1 occupancy of the human α2 (I) collagen (COL1A2) promoter was determined by chromatin immunoprecipitation and reverse
transcription (RT) real-time PCR (F). Fli1 mRNA levels were determined by RT real-time PCR (G). The graph represents fold change in type I
collagen protein levels quantified by densitometry (A, B), Fli1 occupancy of the COL1A2 promoter (F), and Fli1 mRNA levels (G) in
comparison to unstimulated controls, which were arbitrarily set at 1. Equal amounts of loading were confirmed by immunoblotting for
β-actin in cytoplasmic extracts and for TATA binding protein (TBP) in nuclear extracts. The values below each blot represent the relative
levels of target molecules normalized by loading controls with densitometry. α1(I), α1(I) procollagen; α2(I), α2(I) procollagen; AU,
arbitrary unit.
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http://arthritis-research.com/content/16/2/R86reverses the pro-fibrotic phenotype of SSc dermal fibro-
blasts by increasing the DNA binding of Fli1 through the
inhibition of the c-Abl /PKC-δ/Fli1 pathway, which isconstitutively activated in those cells [33]. Supporting this
hypothesis, exogenous ET-1 did not affect type I collagen
expression, whereas bosentan suppressed the expression of
Table 1 Viability of systemic sclerosis dermal fibroblasts
in the presence or absence of bosentan, which was






0 10 20 40
0 96.5 ± 0.05 98.8 ± 0.24 96.3 ± 0.70 97.3 ± 1.52
24 97.3 ± 1.13 97.8 ± 1.13 97.6 ± 1.68 96.3 ± 0.72
48 95.6 ± 0.64 96.2 ± 0.55 96.8 ± 0.25 95.1 ± 0.18
The impact of bosentan on cell viability was evaluated by trypan blue
exclusion test. The percentage of cell viability was calculated according to the
following formula: % cell viability = (viable cell count/total cell count) × 100.
Data are expressed as the mean ± SD of results in three
independent experiments.
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http://arthritis-research.com/content/16/2/R86c-Abl and PKC-δ, decreased the nuclear localization of
PKC-δ and Fli1 phosphorylation at threonine 312, and
eventually increased the DNA binding ability of Fli1 to the
COL1A2 promoter resulting in the reduction of type I col-
lagen expression in SSc dermal fibroblasts. Furthermore,
bosentan increased the expression levels of Fli1 protein in
lesional dermal fibroblasts of BLM-treated mice. As the
protein stability of Fli1 increases when Fli1 binds to DNA,
and is protected from degradation, these in vivo data sug-
gest that bosentan prevents the development of dermal fi-
brosis in BLM-treated mice by increasing the DNA
binding of Fli1 in lesional dermal fibroblasts. Collectively,
these results indicate that the anti-fibrotic effect of bosen-
tan on SSc dermal fibroblasts and BLM-induced SSc mur-
ine model is at least partly attributable to the increase in
the DNA binding ability of Fli1.
ET-1 induces a pro-fibrotic phenotype in fibroblasts
through increasing the expression of extracellular matrix
(ECM) proteins, such as type I and III collagen and fi-
bronectin, and decreasing the expression of matrix me-
talloproteinase 1 [39,40], therefore the blockade of ET-1
signaling has been thought to be a potential therapeutic
strategy for fibrotic disorders, including SSc. The first
study of the anti-fibrotic effect of bosentan on SSc fibro-
blasts was reported in 2004 by Shi-Wen et al. A series of
studies from their group demonstrated that bosentan
suppresses the expression of α-SMA, type I collagen, fi-
bronectin, and CCN2 in SSc lung fibroblasts and ET-1 is
a downstream mediator of pro-fibrotic responses to
TGF-β in human lung fibroblasts [8,10,11]. Following
these, Lagares et al. [12] revealed that these previous
findings in lung fibroblasts are reproducible in dermal fi-
broblasts in in vitro experiments and in vivo animal
models. Thus, ET-1 and its receptor antagonists have
currently drawn much attention in the field of research
on the mechanism and treatment of fibrotic disorders,
but the detailed molecular mechanism explaining their
effects has remained to be clarified. Since ET-1 induces
a prominent fibrotic response even in the absence ofSmad2/3 activation, which are important intracellular
second messengers of TGF-β signaling especially in the
regulation of the fibrotic gene program, ET-1 appears to
inactivate a potent master repressor acting on a set of
fibrosis-related genes. Taking into account that gene si-
lencing of Fli1 results in the induction of COL1A2 gene
expression up to the level much greater than that
achieved by TGF-β1 stimulation [23,25,29,32,33,41], we
speculated that Fli1 may be inactivated in response to
ET-1 stimulation. Consistent with this idea, a responsive
element of COL1A2 promoter to ET-1 was located be-
tween −353 and −264 bp, including the Fli1 binding site,
and ET-1 activated c-Abl and PKC-δ, resulting in Fli1
inactivation through its phosphorylation at threonine
312. Although other mechanisms may be involved in the
pro-fibrotic effect of ET-1, the current data indicate that
Fli1 largely contributes to the mechanism explaining the
potent pro-fibrotic effect of ET-1 in dermal fibroblasts.
Although bosentan attenuates BLM-induced dermal and
pulmonary fibrosis in animal models [12,42-44], its effi-
cacy on skin sclerosis and ILD in SSc, to our best know-
ledge, has been reported to be limited [20,21]. In addition
to the difference in the pathological process between SSc
and animal models, lower potential of bosentan for good
tissue distribution, which is estimated around 1% [22], has
been cited as a cause of the unsuccessful outcome of oral
bosentan therapy against skin sclerosis and ILD in SSc.
Considering that the average peak plasma concentration
after a single dose of 125 mg of bosentan, which is a max-
imal dose clinically used in humans, is 1,584 ng/ml (2.87
μM) in Caucasian and 1,922 ng/ml (3.48 μM) in Japanese
subjects [45], 10 μM of bosentan, which has been used for
in vitro experiments with fibroblasts, appears to be much
higher than the concentration of bosentan in human skin
tissue. In the present study, bosentan suppressed type I
collagen expression in a dose-dependent manner up to 40
μM without affecting cell viability in SSc dermal fibro-
blasts, suggesting that endothelin receptor antagonists
with better tissue distribution and tolerability may have
potential as disease-modifying drugs targeting skin scler-
osis and ILD in SSc by directly inactivating fibroblasts.
According to a previous report by Wang et al. [46],
the expression of Fli1 is strongly suppressed at the tran-
scription level by an epigenetic mechanism in SSc der-
mal fibroblasts. The authors demonstrated that the
acetylation levels of histone H3 and H4 are decreased,
while the methylation levels of CpG islands are in-
creased, in the promoter region of the FLI1 gene in SSc
dermal fibroblasts compared with normal dermal fibro-
blasts, suggesting that the decrease in FLI1 gene expres-
sion contributes to the developmental process of SSc as
a potential predisposing factor. The most important ob-
servation in the present study was that bosentan re-
versed the decreased expression of Fli1 protein without
Figure 6 Bosentan prevented the development of dermal fibrosis, at least partially, by increasing the expression of Fli1 protein in
lesional dermal fibroblasts of bleomycin (BLM)-induced systemic sclerosis (SSc) murine model. Wild-type C57BL/6 mice were injected with
BLM (200 μg) or PBS into the skin of the back for 3 weeks. In some mice, bosentan (BOS) was administered intraperitoneally for 4 weeks from 1
week before BLM treatment. (A) The thickness of the skin on the back was evaluated by hematoxylin and eosin staining. The graph represents
fold change in the dermal thickness in comparison to PBS-treated mice without bosentan administration, which was arbitrarily set at 1. (B) The
expression levels of Fli1 protein were determined by immunohistochemistry. The arrows represent Fli1-positive dermal fibroblasts. (C) Double
immunofluorescence for Fli1 (red) and α-SMA (green). Blue signals of nuclei were detected with 4′,6-diamidino-2-phenylindole (DAPI). The bottom
panels represent the overlay of the three above. *P <0.05 versus PBS-treated mice without bosentan. **P <0.05 versus BLM-treated mice without
bosentan. AU, arbitrary unit.
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blasts. These results suggest that bosentan can increase
Fli1 protein levels regardless of the degree of epigenetic
transcriptional suppression in those cells. Given that
the reversion of epigenetically repressed disease-related
genes by drugs is a general idea for the treatment of
various diseases, bosentan may serve as a disease-
modifying drug for SSc. Although the efficacy of bosen-
tan on skin sclerosis and ILD is limited, recent papers
demonstrated the potential of bosentan as a disease-
modifying drug for SSc vasculopathy. In addition to theprevention of new digital ulcers by bosentan [15,16],
Guiducci et al. [47] revealed that one-year treatment
with bosentan significantly decreases the number of
advanced nailfold capillary changes, such as capillary
disorganization, ramified capillaries, and capillary loss,
while increasing the number of relatively early changes,
including enlarged capillaries, megacapillaries, and he-
morrhage, in SSc patients. These clinical findings sug-
gest that the effect of endothelin receptor antagonists on
SSc vasculopathy goes beyond the reversal of the potent
vasoconstrictive effects of endothelin. This notion has
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http://arthritis-research.com/content/16/2/R86been supported by some experimental data. For example,
ET-1 has a potent mitogenic action on fibroblasts and
vascular smooth muscle cells [48,49]. Furthermore, ET-1
prolongs the survival of myofibroblasts by preventing
apoptosis [8]. Moreover, ET-1 triggers the pathological
inflammation by modulating the expression of cell adhe-
sion molecules on endothelial cells [50] and by promot-
ing the production of free radical and fibrosis-inducing
cytokines, such as monocyte chemoattractant protein-1
and TGF-β, from macrophages [51]. These proliferative,
pro-fibrotic, and pro-inflammatory effects of ET-1 con-
tribute to the development of SSc vasculopathy. Consid-
ering that endothelial Fli1 deficiency contributes to the
development of SSc vasculopathy [52], bosentan may
exert its disease-modifying effect on SSc vasculopathy by
increasing endothelial Fli1 expression. The research re-
garding the effect of bosentan on endothelial Fli1 defi-
ciency is currently underway in our laboratory.
Similar to bosentan, our latest paper demonstrated
that imatinib reverses the decreased expression of Fli1 in
SSc dermal fibroblasts by increasing its protein stability
and without affecting its gene expression status [33],
suggesting that imatinib is a potential disease-modifying
drug for SSc patients. Consistent with this idea, imatinib
moderately improved skin sclerosis of SSc patients in a
couple of case reports [53,54] and case series [55-57].
Although imatinib was poorly tolerated and failed to
show a significant effect on skin sclerosis of SSc patients
in a couple of clinical trials [58], previous case reports
suggest that some derivatives of imatinib with a better
tolerability may be effective for skin sclerosis in a certain
subset of SSc patients. Similarly, the clinical response of
digital ulcers associated with SSc to bosentan varies
from patients to patients [15,16]. Given that SSc is a
multifactorial disease caused by a complex interaction be-
tween hereditary factors and environmental influences,
these clinical data suggest that imatinib and bosentan may
target some disease-associated factors, leading to the
modification of the natural disease course in a certain sub-
set of SSc patients. Given that both of c-Abl tyrosine kin-
ase inhibitors and endothelin receptor antagonists target
Fli1, a potential predisposing factor of SSc, further studies
on the association between the degree of Fli1 suppression
and the clinical efficacy of these drugs may provide us
some clue to properly select good responders and effect-
ively administer these treatments for SSc patients.
In the present study, 200 nM of ET-1 showed the
maximal stimulatory effect on type I collagen expression
in normal human dermal fibroblasts. However, previous
reports demonstrated that 100 nM of ET-1 exhibits a sig-
nificant stimulatory effect on the expression levels of type
I collagen, fibronectin, fibrillin-1, and α-SMA and the gel
contraction in murine embryonic fibroblasts and human
normal lung and dermal fibroblasts [8,9,12,40,59]. Thisdiscrepancy may be attributable to the different sensitivity
of fibroblasts to ET-1 and/or to the different experimental
conditions between each study, but the actual reason is
unclear.
Conclusions
We herein reported the first study regarding the detailed
molecular mechanism underlying the pro-fibrotic effect
of ET-1 on normal dermal fibroblasts and the anti-
fibrotic effect of bosentan on SSc dermal fibroblasts, in
which transcription factor Fli1, a potential predisposing
factor in SSc, is an important target. Although the effi-
cacy of bosentan for dermal and pulmonary fibrotic con-
ditions associated with SSc is limited, the present
observation definitely provides us with a useful clue to
further explore the potential of the upcoming new dual
endothelin receptor antagonists with better clinical ef-
fects as disease-modifying drugs for SSc.
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